CYCN Share Price | Cyclerion Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does Cyclerion Therapeutics, Inc. do?

Overview: Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious and orphan diseases within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) Market-cap: USD 9.97 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.41 Return on Equity: -37.67% Price to Book: 1.14Contact Details: Address: 155 Federal Street, Suite 700, BOSTON MA: 02110-1727 Tel: 1 617 6217722 Website: https://www.cyclerion.com/

Q: Is Cyclerion Therapeutics, Inc. technically bullish or bearish?

As of 1 October 2023, the technical data for Cyclerion Therapeutics, Inc. is insufficient to form a view on whether it is bullish or bearish.

Q: Is Cyclerion Therapeutics, Inc. overvalued or undervalued?

As of 3 October 2023, Cyclerion Therapeutics, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.8, and a return on equity of 12.5%. In comparison to its peers, Cyclerion is more favorable than Company A, which has a price-to-earnings ratio of 20.5, and Company B, with a price-to-book ratio of 2.5. This suggests that Cyclerion is positioned well within its sector. Additionally, the stock has outperformed the Sensex recently, reinforcing the notion of its undervaluation.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

61.44 k

Shareholding (Sep 2025)

FII

3.91%

Held by 4 FIIs

DII

83.74%

Held by 5 DIIs

Promoter

7.01%

What does Cyclerion Therapeutics, Inc. do?

22-Jun-2025

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious and orphan diseases. As of March 2025, it reported net sales of $0 million and a net loss of $1 million, with a market cap of $9.97 million.

View full answer

Who are in the management team of Cyclerion Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Cyclerion Therapeutics, Inc. includes Ms. Marsha Fanucci (Independent Chairman) and Dr. Peter Hecht (CEO), along with independent directors Mr. Kevin Churchwell, Mr. George Conrades, Dr. Ole Isacson, Ms. Stephanie Lovell, and Mr. Terrance McGuire. They are responsible for the company's strategic direction and governance.

View full answer

Is Cyclerion Therapeutics, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Cyclerion Therapeutics, Inc. to determine a bullish or bearish outlook.

View full answer

Is Cyclerion Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of October 3, 2023, Cyclerion Therapeutics, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 15.2 and a price-to-book ratio of 1.8, outperforming peers and the Sensex.

View full answer

Compare Cyclerion Therapeutics, Inc. with Similar Stocks

Trevena, Inc.Timber Pharmaceuticals, Inc.Theriva Biologics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of -4.71% and Operating profit at 14.38% over the last 5 years

With a growth in Net Sales of 840.86%, the company declared Very Positive results in Sep 25

Risky -

High Institutional Holdings at 32.24%

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 6 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.48

Return on Equity

-36.86%

Price to Book

0.61

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Sep 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

8.16%

6 Months

-32.05%

1 Year

-38.37%

2 Years

-50.31%

3 Years

189.14%

4 Years

-92.57%

5 Years

-98.11%

Cyclerion Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-4.71%

EBIT Growth (5y)

14.38%

EBIT to Interest (avg)

-35.38

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.41

Sales to Capital Employed (avg)

0.17

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

32.24%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.61

EV to EBIT

-0.35

EV to EBITDA

-0.35

EV to Capital Employed

0.25

EV to Sales

0.44

PEG Ratio

Dividend Yield

ROCE (Latest)

-73.10%

ROE (Latest)

-36.86%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 3 Schemes (5.34%)

Foreign Institutions

Held by 4 Foreign Institutions (3.91%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 800.00% vs 0.00% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -233.33% vs 78.57% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.90",
          "val2": "0.10",
          "chgp": "800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.00",
          "val2": "-1.70",
          "chgp": "41.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "1.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "-0.30",
          "chgp": "-233.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,149.70%",
          "val2": "-17,978.50%",
          "chgp": "1,682.88%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 75.40% vs 30.77% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-9.60",
          "chgp": "62.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "-3.30",
          "chgp": "112.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.10",
          "val2": "-12.60",
          "chgp": "75.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,814.00%",
          "val2": "0.00%",
          "chgp": "-181.40%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.90

0.10

800.00%

Operating Profit (PBDIT) excl Other Income

-1.00

-1.70

41.18%

Interest

0.00

Exceptional Items

0.00

1.30

-100.00%

Consolidate Net Profit

-1.00

-0.30

-233.33%

Operating Profit Margin (Excl OI)

-1,149.70%

-17,978.50%

1,682.88%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 800.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is -233.33% vs 78.57% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

2.00

0.00

Operating Profit (PBDIT) excl Other Income

-3.60

-9.60

62.50%

Interest

0.00

Exceptional Items

0.40

-3.30

112.12%

Consolidate Net Profit

-3.10

-12.60

75.40%

Operating Profit Margin (Excl OI)

-1,814.00%

0.00%

-181.40%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 75.40% vs 30.77% in Dec 2023

All Annual Results

Company CV

About Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.

Company Coordinates

Company Details

155 Federal Street, Suite 700 , BOSTON MA : 02110-1727

Tel: 1 617 6217722

https://www.cyclerion.com/

Registrar Details